Johns Hopkins Aramco Healthcare (JHAH) has become the first hospital in the Eastern Province to conduct a stereotactic radiosurgery (SRS) using TrueBeam accelerators. This advanced technology expands the treatment options available to patients.
“The brain is particularly sensitive, so we started using SRS on patients with certain types of brain tumors,” said Dr. Majid Othman, radiation oncology unit head. SRS allows for higher doses of radiation to be more precisely delivered.
JHAH has kept up with the advances of linear accelerator technology. The recently integrated Varian Truebeam technology allows the JHAH radiation oncology team to deliver more focused treatments.
For nearly 25 years, JHAH’s Oncology Institute has provided its medical staff with the latest tools and technologies to treat cancer and other blood disorders, using linear accelerators to deliver high-intensity radiation beams to destroy cancer cells.
SRS can also be used to treat lung, liver, adrenal and other soft tissue tumors. When other areas of the body are the focus, the treatment is called stereotactic body radiotherapy (SBRT).
JHAH’s Oncology Institute prides itself not only on its academic research and specialized education, but also on its clinical services and how they can help patients. JHAH offers an extensive range of cancer-care services and facilities, including a Radiation Therapy Unit and a Blood Disorders Center.
With the first tumor registry in the Middle East and North Africa region, JHAH supports academic research, and its team includes internationally recognized speakers. In addition, JHAH is an approved Kingdom of Saudi Arabia Ministry of Health (KSA MOH) Fellowship Program site in oncology and hematology, and the first oncology center developed in the Eastern Province of Saudi Arabia.